Middle East Cystic Fibrosis Association MECFA

MECFA Blog

The Middle East CF Association

The Middle East CF Association (MECFA) is working to make lives better for people with cystic fibrosis. Christine Noke is the co-founder...

Protalix, SarcoMed Partner to Advance PRX-110 for Pulmonary Sarcoidosis

Protalix Biotherapeutics and SarcoMed USA have entered into an exclusive worldwide license agreement to advance PRX-110 (alidornase alfa)...

Electromed Resumes Study of SmartVest

Electromed has resumed a study seeking to assess the effects of SmartVest, an inflatable vest that can be used to deliver high-frequency...

Tobramycin, Inhaled Antibiotic, Eases Symptoms, Study in Off-label Use Finds

Off-label use of the inhaled antibiotic tobramycin lowered sputum production, and eased shortness of breath, and cough in people with...

UK Trial to Investigate Safety of Lowering CF Treatment Burden via Kaftrio

The National Institute for Health Research (NIHR) awarded a grant worth more than £1.5 million (about $2.1 million) to support a U.K....

Safety, tolerability of combination therapy sustained in children with cystic fibrosis

Combination therapy with lumacaftor/ivacaftor was safe and well tolerated for up to 120 weeks in children aged 6 to 11 years with the...

CF Foundation Has Awarded Up to $3M to Kinnear Pharmaceuticals for Anti-Infective

The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum...

Minority Patients Miss Out On Life-Saving Cystic Fibrosis Drugs Due to Genetic Test Limitations

Poor Representation of Non-White CF Patients in Drug Trials Has Effectively Prohibited Them From Receiving the Most Effective Treatments,...

CF Foundation Grant Supports Testing of CSA-131 Against Resistant Bacteria

The Cystic Fibrosis Foundation (CFF) has given Kinnear Pharmaceuticals up to $3 million to conduct the laboratory tests of CSA-131, a...

U of M doctor brings cystic fibrosis awareness to Egypt

ANN ARBOR — Doctors in Egypt weren’t aware of the prevalence of Cystic Fibrosis (CF) in their country until the efforts of a University...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p